Your browser doesn't support javascript.
loading
Guidance on the need for contraception related to use of pharmaceuticals: the Japan Agency for Medical Research and Development Study Group for providing information on the proper use of pharmaceuticals in patients with reproductive potential.
Suzuki, Nao; Takai, Yasushi; Yonemura, Masahito; Negoro, Hiromitsu; Motonaga, Shinya; Fujishiro, Noriko; Nakamura, Eishin; Takae, Seido; Yoshida, Saori; Uesugi, Koji; Ohira, Takashi; Katsura, Aiko; Fujiwara, Michio; Horiguchi, Itsuko; Kosaki, Kenjiro; Onodera, Hiroshi; Nishiyama, Hiroyuki.
  • Suzuki N; Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan. nao@marianna-u.ac.jp.
  • Takai Y; Department of Obstetrics and Gynecology, Saitama Medical Center, 1981 Kamoda, Kawagoe-shi, Saitama, Japan.
  • Yonemura M; Department of Pharmacy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, Japan.
  • Negoro H; Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, Japan.
  • Motonaga S; Pharmacovigilance Section, Office of Clinical Research Support, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, Japan.
  • Fujishiro N; Pharmacovigilance Section, Office of Clinical Research Support, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, Japan.
  • Nakamura E; Department of Obstetrics and Gynecology, Saitama Medical Center, 1981 Kamoda, Kawagoe-shi, Saitama, Japan.
  • Takae S; Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan.
  • Yoshida S; Qol Co., Ltd, 4-3-1 Toranomon, Minato-ku, Tokyo, Japan.
  • Uesugi K; Pfizer R&D Japan G.K, 3-22-7 Yoyogi, Shibuya-ku, Tokyo, Japan.
  • Ohira T; Pharmaceutical Research and Manufacturers of America, 3-7-8 Toranomon, Minato-ku, Tokyo, Japan.
  • Katsura A; Takeda Pharmaceutical Company Limited, 2-1-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan.
  • Fujiwara M; Japan Pharmaceutical Manufacturers Association, 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan.
  • Horiguchi I; Novartis Pharma K.K, 1-23-1 Toranomon, Minato-ku, Tokyo, Japan.
  • Kosaki K; European Federation of Pharmaceutical Industries and Associations, Japan, 2-1-1 Osaki, Shinagawa-ku, Tokyo, Japan.
  • Onodera H; Japan Pharmaceutical Manufacturers Association, 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan.
  • Nishiyama H; The Support Center for Clinical Pharmacy Education and Research, Tokyo University of Science, 1-3 Kagurazaka, Shinjuku-ku, Tokyo, Japan.
Int J Clin Oncol ; 27(5): 829-839, 2022 May.
Article en En | MEDLINE | ID: mdl-35347493
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Investigación / Anticoncepción Tipo de estudio: Guideline Límite: Adolescent / Adult / Humans País como asunto: America do norte / Asia Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Investigación / Anticoncepción Tipo de estudio: Guideline Límite: Adolescent / Adult / Humans País como asunto: America do norte / Asia Idioma: En Año: 2022 Tipo del documento: Article